Completed PHASE2 INTERVENTIONAL 3-arm NCT00537082

Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis (MS)

A 6-month, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study Comparing Efficacy and Safety of FTY720 0.5 mg and 1.25 mg Administered Orally Once Daily in Patients With Relapsing Multiple Sclerosis

Sponsor: Novartis

Conditions Multiple Sclerosis

Interventions FTY720 Placebo

Updated 7 times since 2017 Last updated: Apr 19, 2011 Started: Sep 30, 2007 Primary completion: Feb 28, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Multiple Sclerosis, this trial is completed. The trial is conducted by Novartis and has accumulated 7 data snapshots since 2007. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE2
Sep 2025 — Jan 2026 [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Sep 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis
Tanabe Pharma Corporation

Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Chiba, Japan , Ehime, Japan , Fukuoka, Japan , Gunma, Japan , Hyōgo, Japan , Ibaraki, Japan , Kanagawa, Japan , Kyoto, Japan , Niigata, Japan , Numakunai, Japan and 5 more locations